Overview:

Summary

The industry analysis specialist, has released its new report, “Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. The report identifies the key trends shaping and driving the global Hepatitis A Preventive Vaccines market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hepatitis A Preventive Vaccines sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimated the global hepatitis A preventive vaccines market to be worth $476m in 2010, and it is forecast to grow at 6.2% annually for the next seven years to reach $726m by 2017. This medium growth is primarily attributed to growth in vaccination coverage due to increase in recommendation for hepatitis A vaccination. The growth is further supported by increase in tourist traffic globally as hepatitis A vaccines are used as traveler vaccines by tourists. However, supply issues with some vaccines acts as a barrier to the market.

Scope

The report provides information on the key drivers and challenges of the Hepatitis A Preventive Vaccines market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hepatitis A Preventive Vaccines market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates are very few in number and are majorly product extension of an already approved vaccines.  They fall under major vaccine class inactivated vaccine. Analysis of the current and future competition in the seven key countries Hepatitis A Preventive Vaccines market. Key market players covered are Merck and Co., GlaxoSmithKline, Sanofi Pasteur MSD and Variation Biotechnologies.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hepatitis A Preventive Vaccines therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis A Preventive Vaccines market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hepatitis A Preventive Vaccines market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis A Preventive Vaccines market landscape? – Identify, understand and capitalize."

Companies Mentioned
"Merck & Co
GlaxoSmithKline
Sanofi Pasteur MSD
Variation Biotechnologies

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Hepatitis A preventive Vaccines: Introduction 6
2.1 Disease Overview of Hepatitis A 6
2.2 Etiology of Hepatitis A 6
2.3 Risk Factors of Hepatitis A 6
2.4 Pathopysiology of Hepatitis A 7
2.5 Symptoms of Hepatitis A 7
2.6 Epidemiology of Hepatitis A 8
2.7 Diagnosis of Hepatitis A 8
2.8 Treatment and Management Pattern of Hepatitis A 8
2.9 GlobalData Pipeline Report Guidance 9
3 Hepatitis A Preventive Vaccines : Market Characterization 10
3.1 Hepatitis A Preventive Vaccines, Global Market Size 10
3.2 Hepatitis A Preventive Vaccines Market Forecast and Compound Annual Growth Rate 11
3.3 Hepatitis A Preventive Vaccines Market – The US (2005-2010) 12
3.4 Hepatitis A Preventive Vaccines Market Forecast – The US (2010-2017) 13
3.5 Hepatitis A Preventive Vaccines Market – The UK (2005-2010) 14
3.6 Hepatitis A Preventive Vaccines Market Forecast – The UK (2010-2017) 15
3.7 Hepatitis A Preventive Vaccines Market – Germany (2005-2010) 16
3.8 Hepatitis A Preventive Vaccines Market Forecast – Germany (2010-2017) 17
3.9 Hepatitis A Preventive Vaccines Market – France (2005-2010) 18
3.10 Hepatitis A Preventive Vaccines Market Forecast – France (2010-2017) 19
3.11 Hepatitis A Preventive Vaccines Market – Spain (2005-2010) 20
3.12 Hepatitis A Preventive Vaccines Market Forecast – Spain (2010-2017) 21
3.13 Hepatitis A Preventive Vaccines Market – Italy (2005-2010) 22
3.14 Hepatitis A Preventive Vaccines Market Forecast – Italy (2010-2017) 23
3.15 Hepatitis A Preventive Vaccines Market – Japan (2005-2010) 24
3.16 Hepatitis A Preventive Vaccines Market Forecast – Japan (2010-2017) 25
3.17 Drivers and Barriers for the MRSA Market 26
3.17.1 Hepatitis A Preventive Vaccines Market Drivers 26
3.17.2 Hepatitis A Preventive Vaccines Market Barriers 26
3.18 Opportunity and Unmet Need 27
3.19 Key Takeaway 27
4 Hepatitis A Preventive Vaccines: Competitive Assessment 28
4.1 Overview 28
4.2 Strategic Competitor Assessment 28
4.3 Product Profile for the Major Marketed Products in the Hepatitis A preventive Vaccines Market 29
4.3.1 Twinrix 29
4.3.2 Havrix 30
4.3.3 Vaqta 31
4.3.4 Ambirix 32
4.3.5 Avaxim 34
4.4 Key Takeaway 35
5 Hepatitis A Preventive Vaccines: Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 Hepatitis A Preventive Vaccines  – Pipeline analysis by Phases of Development 36
5.3.1 Hepatitis A Preventive Vaccines – Phase III Pipeline 36
5.3.2 Hepatitis A Preventive Vaccines – Preclinical Pipeline 37
5.4 Hepatitis A Preventive Vaccines – Pipeline by Mechanism of Action 37
5.5 Technology Trends Analytical Framework 38
5.6 Hepatitis A Preventive Vaccines – Promising Vaccines Under Clinical Development 39
5.7 Most Promising Vaccine Profiles 39
5.7.1 Oral Hep A 39
5.8 Key Takeaway 39
6 Hepatitis A Preventive Vaccine: Clinical Trials Mapping 40
6.1 Clinical Trials by Region/Country (US, EU5 & Japan) 40
6.2 Clinical Trials by Phase of Clinical Development 41
6.3 Clinical Trials by Trial Status 42
6.4 Prominent Sponsors 42
6.5 Brief Profiles of Top Ten Companies Participating in Preventive Vaccines Clinical Trials 42
7 Hepatitis A Preventive Vaccines: Strategic Assessment 43
7.1 Key Events Impacting the Future Market 43
7.1.1 Hepatitis A Preventive Vaccines: Implications for Future Market Competition 44
8 Hepatitis A Preventive Vaccines: Future Players 45
8.1 Introduction 45
8.2 Company Profiles 46
8.2.1 Merck & Co 46
8.2.2 GlaxoSmithKline 50
8.2.3 Sanofi Pasteur MSD 55
8.2.4 Variation Biotechnologies 55
8.3 Key Takeaway 56
9 Hepatitis A Preventive Vaccines: Appendix 57
9.1 Definition 57
9.2 Acronyms 57
9.3 Research Methodology 57
9.3.1 Coverage 57
9.3.2 Secondary Research 58
9.3.3 Forecasting 58
9.3.4 Primary Research 61
9.3.5 Expert Panel Validation 61
9.4 Contact Us 61
9.5 Disclaimer 61
9.6 Bibliography 62"

1.1 List of Tables
Table 1: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2005–2010 10
Table 2: Hepatitis A Preventive Vaccines, Major Market, Global, Forecasts ($m), 2010–2017 11
Table 3: Hepatitis A Preventive Vaccines , The US, Revenue ($m), 2005–2010 12
Table 4: Hepatitis A Preventive Vaccines Market, The US, Forecasts ($m), 2010–2017 13
Table 5: Hepatitis A Preventive Vaccines Market, The UK, Forecasts ($m), 2010–2017 15
Table 6: Hepatitis A Preventive Vaccines, Germany, Revenue ($m), 2005–2010 16
Table 7: Hepatitis A Preventive Vaccines Market, Germany, Forecasts ($m), 2010–2017 17
Table 8: Hepatitis A Preventive Vaccines, France, Revenue ($m), 2005–2010 18
Table 9: Hepatitis A Preventive Vaccines Market, France, Forecasts ($m), 2010–2017 19
Table 10: Hepatitis A Preventive Vaccines, Spain, Revenue ($m), 2005–2010 20
Table 11: Hepatitis A Preventive Vaccines Market, Spain, Forecasts ($m), 2010–2017 21
Table 12: Hepatitis A Preventive Vaccines, Italy, Revenue ($m), 2005–2010 22
Table 13: Hepatitis A Preventive Vaccines Market, Italy, Forecasts ($m), 2010–2017 23
Table 14: Hepatitis A Preventive Vaccines, Japan, Revenue ($m), 2005–2010 24
Table 15: Hepatitis A Preventive Vaccines Market, Japan , Forecasts ($m), 2010–2017 25
Table 16:Havrix Trial Data 30
Table 17:Hepatitis A – Major Vaccines Dosing Schedule 34
Table 18: Major Market Products Comparison in Hepatitis A Preventive Vaccines Market, 2010 34
Table 19: Hepatitis A Preventive Vaccines, Phase III Pipeline, 2010 36
Table 20: Hepatitis A Preventive Vaccines, Preclinical Pipeline, 2010 37
Table 21: Hepatitis A Preventive Vaccines – Most Promising Vaccines Under Development, 2010 39
Table 22: Hepatitis A Preventive Vaccines – Clinical Trials by Country, 2010 40
Table 23: Hepatitis A Preventive Vaccines, Major Markets – Clinical Trials by Phase, 2010 41
Table 24: Hepatitis A Preventive Vaccines, Major Markets, Clinical Trials by Development Status, 2010 42
Table 25: Hepatitis A Preventive Vaccines, Major Markets, Prominent Sponsors, 2010 42
Table 26: Hepatitis A Preventive Vaccines, Major Markets, Clinical Trials of Top Companies by Phase, 2010 42
Table 27: Merck & Co. Deals, Alliances and Partnerships 48
Table 28: Merck & Co – Hepatitis A Marketed  Products, 2010 50
Table 29: GlaxoSmithKline Deals, Alliances and Partnerships 51
Table 30:GalaxoSmithKline Marketed  Products, 2010 54
Table 31: Sanofi Pasteur MSD Marketed  Products, 2010 55
Table 32: Variation Biotechnologies Deals, Alliances and partnerships 55
Table 33: Variation Biotechnologies Pipeline Products, 2010 56"

1.2 List of Figures
Figure 1: Hepatitis A – Pathophysiology 7
Figure 2: Hepatitis A Preventive Vaccines Market, Global, Revenue ($m), 2005–2010 10
Figure 3: Hepatitis A Preventive Vaccines Market, Global, Forecast ($m), 2010–2017 11
Figure 4: Hepatitis A Preventive Vaccines Market, The US,  Revenue ($m), 2005–2010 12
Figure 5: Hepatitis A Preventive Vaccines Market, The US, Forecast ($m), 2010–2017 13
Figure 6:  Hepatitis A Preventive Vaccines Market, The UK, Revenue ($m), 2005–2010 14
Figure 7: Hepatitis A Preventive Vaccines Market, The UK, Forecast ($m), 2010–2017 15
Figure 8: Hepatitis A Preventive Vaccines Market, Germany , Revenue ($m), 2005–2010 16
Figure 9: Hepatitis A Preventive Vaccines Market, Germany, Forecast ($m), 2010–2017 17
Figure 10: Hepatitis A Preventive Vaccines Market, France, Revenue ($m), 2005–2010 18
Figure 11: Hepatitis A Preventive Vaccines Market, France, Forecast ($m), 2010–2017 19
Figure 12: Hepatitis A Preventive Vaccines Market, Spain, Revenue ($m), 2005–2010 20
Figure 13 Hepatitis A Preventive Vaccines Market, Spain, Forecast ($m), 2010–2017 21
Figure 14: Hepatitis A Preventive Vaccines Market, Italy, Revenue ($m), 2005–2010 22
Figure 15: Hepatitis A Preventive Vaccines Market, Italy, Forecast ($m), 2010–2017 23
Figure 16: Hepatitis A Preventive Vaccines Market, Japan, Revenue ($m), 2005–2010 24
Figure 17: Hepatitis A Preventive Vaccines Market, Japan, Forecast ($m), 2010–2017 25
Figure 18: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines Market 27
Figure 19: Strategic Competitor Assessment, 2010 28
Figure 20: Hepatitis A Preventive Vaccines Pipeline by Phases of Development, 2010 36
Figure 21: Hepatitis A preventive Vaccines Market – Pipeline by Mechanism of Action, 2010 37
Figure 22: Technology Trends Analytic Framework for the Hepatitis A Preventive Vaccines Pipeline, 2010 38
Figure 23: Technology Trends Analytic Framework of the Hepatitis A Preventive Vaccines Pipeline – Description, 2010 38
Figure 24: Hepatitis A Preventive Vaccines, Global, Clinical Trials by Country, 2010 40
Figure 25: Hepatitis A Preventive Vaccines, Major Markets – Clinical Trials by Phase, 2010 41
Figure 26: Hepatitis A Preventive Vaccines, Major Markets, Clinical Trials by Development Status, 2010 42
Figure 27: Hepatitis A Preventive Vaccines, Key Events Impacting the Future Market, 2010 43
Figure 28:  Hepatitis A Preventive Vaccines, Implications for Future Market Competition, 2010 44
Figure 29: Hepatitis A preventive Vaccines Market – Pipeline by Company, 2010 45
Figure 30: GlobalData Market Forecasting Model 60